This study aims to openly test the long-term safety, tolerability and effectiveness of repeated administration of IM/SC ketamine for treatment resistant MDD.
Open-label, single-group study evaluating repeated, individually tailored intramuscular or subcutaneous ketamine (0.3–1.5 mg/kg; up to 3×/week) in treatment-resistant major depressive disorder.
Primary aims are safety and tolerability; secondary assessments include antidepressant effectiveness, cognitive effects using the Neurotrax battery, and exploration of optimal dose, frequency and duration.
Treatment-resistant patients treated with multiple IM/SC ketamine doses (individually tailored; 0.3–1.5 mg/kg).
IM or SC; individualized dosing 0.3–1.5 mg/kg; up to 3x/week; repeated administration